M&A

Merck Expands Oncology Pipeline With ArQule

Published: June 22nd, 2020

The biopharmaceutical giant is paying a 107% premium for the target, which focuses on therapies for treating cancer and rare diseases.

Biopharmaceutical giant Merck & Co. Inc. (MRK) said Monday, Dec. 9, it is buying ArQule Inc. (ARQL) for $20 a share or about $2.7 billion in a move that broadens its pipeline in oncology.

The price tag marks a 107% premium over ArQule’s closing share price on Friday.

Burlington, Mass.-based ArQule focuses on therapies for treating cancer and rare diseases. The company’s lead investigational candidate, ARQ 531, is an inhibitor of an enzyme known as Bruton’s tyrosine kinase. ARQ 531 is in a Phase 2 dose expansion study to treat B-cell malignancies.

The deal announcement came on the same day that ArQule unveiled final results from a Phase 1 study of ARQ 531 at the American Society of Hematology 2019 Annual Meeting & Exposition in Orlando, Fla.

This Content is Only for The Deal Subscribers

The Deal provides actionable, intraday coverage of mergers, acquisitions and all other changes in corporate control to institutional investors, private equity, hedge funds and the firms that serve them.

If you’re already a subscriber, log in to view this article here.

More From M&A

M&A

Drinks With The Deal: King & Spalding's Townsend Talks Business Development

By David Marcus

Published: October 24th, 2024

Keith Townsend, an M&A partner at King & Spalding and co-head of its corporate practice, discusses how he developed business development skills as a young partner and how his firm thinks about its practice mix.

M&A

Drinks With The Deal: Katten's Solomon on Family Office Evolution, Texas Economics

By David Marcus

Published: October 10th, 2024

Katten's Mark Solomon discusses the evolution of family offices over the past generation and how the Dallas economy has changed since he started practicing law in the city in 1985.

M&A

Drinks With The Deal: Jones Day’s Lesnick on Reynolds Work, AI

By David Marcus

Published: September 12th, 2024

Randi Lesnick, co-chair of Jones Day's corporate practice, discusses key deals in her career and issues that AI raises both for law firms and for companies doing deals.

View All From M&A